Reproductive BioMedicine Online
Volume 20, Issue 4 , Pages 565-567, April 2010

LH concentrations do not correlate with pregnancy in rFSH/GnRH antagonist cycles

  • Kevin Doody

      Affiliations

    • Center for Assisted Reproduction, Bedford, Texas, USA
    • ,
  • Paul Devroey

      Affiliations

    • Center for Reproductive Medicine, Universitair Ziekenhuis Brussel, Belgium
    • ,
  • Keith Gordon

      Affiliations

    • Global Medical Affairs, Schering-Plough Kenilworth, NJ, USA
    • ,
  • Han Witjes

      Affiliations

    • Schering-Plough Research Institute, Oss, The Netherlands
    • ,
  • Bernadette Mannaerts

      Affiliations

    • Schering-Plough Research Institute, Oss, The Netherlands
    • Corresponding Author InformationCorresponding author.

Received 2 July 2009; received in revised form 21 September 2009; accepted 30 November 2009. published online 04 February 2010.

Declaration: The authors report no financial or commercial conflicts of interest.

Abstract 

The possible relationship between endogenous LH concentrations and clinical outcome was evaluated in 750 patients treated with a standardized gonadotrophin-releasing hormone (GnRH) antagonist and recombinant FSH (rFSH)-only protocol. Serum LH concentrations were measured during stimulation by a central laboratory and patients were stratified into quantiles of <P25, P25–P75, and >P75. The P25 values were 3.38IU/l, 0.93IU/l, and 0.91IU/l on stimulation days 1, 5, and 8, respectively. The ongoing pregnancy rates per started cycle of patients within the <P25 subset on stimulation day 1, 5, or 8 were highly similar to those in the P25–P75, and >P75 subsets and ranged in the various subsets between 35.0% and 39.5%. In keeping with previous, smaller studies, these findings demonstrate that in good prognosis, non-obese patients endogenous LH in a GnRH antagonist protocol is able to support treatment with rFSH only.

Keywords: endogenous LH, GnRH antagonist protocol, IVF, rFSH

To access this article, please choose from the options below

Login to an existing account or Register a new account.

  • Purchase this article for 31.50 USD (You must login/register to purchase this article)

    Online access for 24 hours. The PDF version can be downloaded as your permanent record.

  • Subscribe to this title

    Get unlimited online access to this article and all other articles in this title 24/7 for one year.

  • Claim access now

    For current subscribers with Society Membership or Account Number.

  • Visit SciVerse ScienceDirect to see if you have access via your institution.
 

 Kevin Doody, MD, received his medical degree and served a residency in Obstetrics and Gynecology at Baylor College of Medicine in Houston. After completing his residency, Dr Doody received subspecialty training at UT Southwestern Medical Center. He completed his fellowship in Reproductive Endocrinology/Infertility in 1989. He is board certified in Obstetrics and Gynecology and subspecialty board certified in Reproductive Endocrinology/Infertility. Dr Doody has been repeatedly honored as one of Fort Worth’s Top Docs, one of Texas’ Super Doctors and one of the Best Doctors in America. Dr Doody was also recognized as Microsoft Physician of the Year 2004.

PII: S1472-6483(09)00303-4

doi:10.1016/j.rbmo.2009.12.019

Reproductive BioMedicine Online
Volume 20, Issue 4 , Pages 565-567, April 2010

Article Tools

* Image Usage & Resolution